Skip to content GD2 CAR-T therapy is an innovative immunotherapy that genetically modifies a patient’s own T cells to recognize and attack neuroblastoma cells expressing the GD2 antigen. This therapy is specifically designed for patients with relapsed or refractory high-risk neuroblastoma and has demonstrated promising clinical outcomes in trials.
Disease Status: High-risk neuroblastoma with persistent, relapsed, or progressive disease after first-line treatment.
Additional Factors: Metastatic disease, MYCN amplification, or resistance to conventional therapies.
Preconditioning: Lymphodepletion before infusion.
Infusion: Precision dosing of GD2-CAR-T cells (recommended: 10×10^6 CAR-positive T cells/kg).
Follow-up: Regular imaging (PET/CT, MRI) and bone marrow assessments post-infusion.
Response Rate: 33% achieved complete remission (CR), with an overall response rate (CR+PR) of 63%.
Survival: 3-year overall survival (OS) of 60% and event-free survival (EFS) of 36% at the recommended dose.
Safety Profile: Most common adverse events were manageable Grade 1-2 cytokine release syndrome (74%).
Optimized by Seraphinite Accelerator
